SPYRE THERAPEUTICS INC (SYRE) Stock Fundamental Analysis

NASDAQ:SYRE • US00773J2024

36.63 USD
+1.79 (+5.14%)
At close: Feb 13, 2026
36.8 USD
+0.17 (+0.46%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall SYRE gets a fundamental rating of 3 out of 10. We evaluated SYRE against 523 industry peers in the Biotechnology industry. While SYRE has a great health rating, there are worries on its profitability. SYRE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SYRE has reported negative net income.
  • SYRE had a negative operating cash flow in the past year.
  • In the past 5 years SYRE always reported negative net income.
  • In the past 5 years SYRE always reported negative operating cash flow.
SYRE Yearly Net Income VS EBIT VS OCF VS FCFSYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • SYRE has a Return On Assets of -29.50%. This is in the better half of the industry: SYRE outperforms 67.50% of its industry peers.
  • SYRE's Return On Equity of -32.75% is fine compared to the rest of the industry. SYRE outperforms 74.38% of its industry peers.
Industry RankSector Rank
ROA -29.5%
ROE -32.75%
ROIC N/A
ROA(3y)-83.74%
ROA(5y)-72.23%
ROE(3y)-110.94%
ROE(5y)-93.82%
ROIC(3y)N/A
ROIC(5y)N/A
SYRE Yearly ROA, ROE, ROICSYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • SYRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRE Yearly Profit, Operating, Gross MarginsSYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SYRE has been increased compared to 1 year ago.
  • Compared to 5 years ago, SYRE has more shares outstanding
  • SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SYRE Yearly Shares OutstandingSYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SYRE Yearly Total Debt VS Total AssetsSYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • SYRE has an Altman-Z score of 29.11. This indicates that SYRE is financially healthy and has little risk of bankruptcy at the moment.
  • SYRE's Altman-Z score of 29.11 is amongst the best of the industry. SYRE outperforms 92.35% of its industry peers.
  • SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.11
ROIC/WACCN/A
WACC12.25%
SYRE Yearly LT Debt VS Equity VS FCFSYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 10.98 indicates that SYRE has no problem at all paying its short term obligations.
  • SYRE has a Current ratio of 10.98. This is amongst the best in the industry. SYRE outperforms 85.47% of its industry peers.
  • SYRE has a Quick Ratio of 10.98. This indicates that SYRE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 10.98, SYRE belongs to the top of the industry, outperforming 85.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.98
Quick Ratio 10.98
SYRE Yearly Current Assets VS Current LiabilitesSYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.81%, which is quite impressive.
  • Looking at the last year, SYRE shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SYRE will show a small growth in Earnings Per Share. The EPS will grow by 3.31% on average per year.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y49.18%
EPS Next 2Y16.09%
EPS Next 3Y9.17%
EPS Next 5Y3.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2030 2031 2032 2033 500M 1B 1.5B
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SYRE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRE Price Earnings VS Forward Price EarningsSYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRE Per share dataSYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.09%
EPS Next 3Y9.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (2/13/2026, 8:00:00 PM)

After market: 36.8 +0.17 (+0.46%)

36.63

+1.79 (+5.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-26
Inst Owners82.73%
Inst Owner ChangeN/A
Ins Owners6.7%
Ins Owner Change-12.59%
Market Cap2.84B
Revenue(TTM)N/A
Net Income(TTM)-149.00M
Analysts89
Price Target57.56 (57.14%)
Short Float %14.15%
Short Ratio14.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.06%
Min EPS beat(2)-0.17%
Max EPS beat(2)80.3%
EPS beat(4)3
Avg EPS beat(4)32.57%
Min EPS beat(4)-0.17%
Max EPS beat(4)80.3%
EPS beat(8)4
Avg EPS beat(8)-40.91%
EPS beat(12)5
Avg EPS beat(12)-176.02%
EPS beat(16)7
Avg EPS beat(16)-130.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.33%
PT rev (3m)6.07%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)19.67%
EPS NY rev (1m)1.51%
EPS NY rev (3m)24.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.25
P/tB 6.25
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS5.86
TBVpS5.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.5%
ROE -32.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.74%
ROA(5y)-72.23%
ROE(3y)-110.94%
ROE(5y)-93.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.98
Quick Ratio 10.98
Altman-Z 29.11
F-Score5
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
EPS Next Y49.18%
EPS Next 2Y16.09%
EPS Next 3Y9.17%
EPS Next 5Y3.31%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.3%
EBIT Next 3Y-7.49%
EBIT Next 5Y-10.76%
FCF growth 1Y-86.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.19%
OCF growth 3YN/A
OCF growth 5YN/A

SPYRE THERAPEUTICS INC / SYRE FAQ

What is the ChartMill fundamental rating of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SYRE.


What is the valuation status of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SPYRE THERAPEUTICS INC (SYRE). This can be considered as Overvalued.


Can you provide the profitability details for SPYRE THERAPEUTICS INC?

SPYRE THERAPEUTICS INC (SYRE) has a profitability rating of 1 / 10.